Go to Top

OXiGENE (OXGN): ZYBRESTAT Plus Avastin Well Tolerated in Second Interim Toxicity Analysis of a Phase 2 Trial

OXiGENE, Inc. (Nasdaq :OXGN)  is a biopharmaceutical company whose mission is finding and developing new and improved therapeutics that can deliver significant medical benefits to patients with cancer and sight-threatening eye diseases and conditions.

OXGN announced that the randomized Phase 2 study evaluating the combination of ZYBRESTAT (fosbretabulin tromethamine or CA4P) and Avastin (bevacizumab) to treat patients with persistent or recurrent ovarian cancer has again demonstrated acceptable tolerability in the second and final scheduled interim toxicity analysis.

The Phase 2 trial was initiated in March 2011 , and is being conducted at more than 80 sites in the U.S.
The Study chair and co-chairs are Bradley Monk , MD, Creighton University School of Medicine , St. Joseph’s Hospital and Medical Center , Phoenix, Arizona , Robert L.Coleman , MD, University of Texas MD Anderson Cancer Center, Houston, Texas and Carol Aghajanian , MD, Memorial Sloan-Kettering Cancer Center , respectively.

According to a meeting of the study’s Safety Review Committee (SRC) no additional pre-specified safety concerns were observed. OXiGENE anticipates that patient accrual for the study will be completed within the next 3-4 months, and that top-line data will be available at the end of the year.

Jai Balkissoon , MD, FACS, OXiGENE’s Vice President Clinical Development, commented:

We are pleased that the second and final interim safety review was acceptable, and that enrollment has significantly increased due to the addition of platinum-resistant ovarian cancer patients, who have very few treatment options available to them. With our collaborators at the GOG and CTEP, we look forward to completing enrollment by mid-year and generating top-line data by year-end. We are hopeful that the efficacy and safety data could support advancing toward a pivotal registration program in ovarian cancer.